Zaks’ impending departure but the latest milestone as Moderna charts year ahead 

As Moderna prioritizes maximizing the reach of its COVID-19 vaccine, Thursday’s announcement of the impending departure of longtime CMO Tal Zaks caps a transformational 14 months for the mRNA company and comes during a year when several of the company’s non-COVID programs could return to the limelight.  

The company’s success in developing and building a commercial infrastructure for its COVID-19 vaccine, its first mRNA program to make it to market, will set the commercial stage for the rest of its pipeline. ...